Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Pharmacovigilance01:19

Pharmacovigilance

917
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
917
Modified Boxplots00:57

Modified Boxplots

9.9K
A standard box and whisker plot informs us about the spread of the data in a given sample. One can identify the minimum value, maximum value, first quartile value, second quartile or median value, and third quartile.
However, the box plot does not tell the reader about outliers - values that lie far from the center of the data. We can modify the standard box and whisker plot to identify the outliers and visualize the actual spread of the data in a sample.
Initially, we calculate the adjusted...
9.9K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

151
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
151
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

200
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PMDedu: Assessing the educational needs of startups and academic investigators focused on pediatric medical device development.

Journal of clinical and translational science·2023
Same journal

Zero-shot reconstruction of mutant spatial transcriptomes.

Patterns (New York, N.Y.)·2026
Same journal

Dendritic nonlinearities mitigate communication costs.

Patterns (New York, N.Y.)·2026
Same journal

Erratum: Agentic AI as a coordination paradigm in digital health and agri-food systems.

Patterns (New York, N.Y.)·2026
Same journal

Spacing effect improves generalization in biological and artificial systems.

Patterns (New York, N.Y.)·2026
Same journal

A multi-modal foundation model for brain disease diagnosis and medical imaging.

Patterns (New York, N.Y.)·2026
Same journal

DuoMod-Net: Logarithmic balancing and geometric refinement for imbalanced semi-supervised medical image segmentation.

Patterns (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jul 29, 2025

Facilitating the Analysis of Immunological Data with Visual Analytic Techniques
10:58

Facilitating the Analysis of Immunological Data with Visual Analytic Techniques

Published on: January 2, 2011

10.2K

Bringing FAIRness to FDA data through visualization.

Juan Espinoza Salomon1,2

  • 1Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

Patterns (New York, N.Y.)
|May 24, 2023
PubMed
Summary
This summary is machine-generated.

Clinical trial diversity remains a challenge, but new methods now allow better data aggregation and visualization. This approach enhances transparency and supports research into improving patient representation in drug development.

Area of Science:

  • Clinical research
  • Health equity
  • Data science

Background:

More Related Videos

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

23.8K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Related Experiment Videos

Last Updated: Jul 29, 2025

Facilitating the Analysis of Immunological Data with Visual Analytic Techniques
10:58

Facilitating the Analysis of Immunological Data with Visual Analytic Techniques

Published on: January 2, 2011

10.2K
Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

23.8K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
  • Improving representation and inclusion in clinical trials for new medicinal products has been a priority for federal agencies for over 20 years.
  • Accessing data to evaluate progress in clinical trial diversity has been historically challenging.
  • Lack of accessible data hinders efforts to understand and address disparities in clinical research.